178 related articles for article (PubMed ID: 19118070)
1. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Ribas A; Comin-Anduix B; Economou JS; Donahue TR; de la Rocha P; Morris LF; Jalil J; Dissette VB; Shintaku IP; Glaspy JA; Gomez-Navarro J; Cochran AJ
Clin Cancer Res; 2009 Jan; 15(1):390-9. PubMed ID: 19118070
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
Speeckaert R; Vermaelen K; van Geel N; Autier P; Lambert J; Haspeslagh M; van Gele M; Thielemans K; Neyns B; Roche N; Verbeke N; Deron P; Speeckaert M; Brochez L
Eur J Cancer; 2012 Sep; 48(13):2004-11. PubMed ID: 22033321
[TBL] [Abstract][Full Text] [Related]
3. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Huang RR; Jalil J; Economou JS; Chmielowski B; Koya RC; Mok S; Sazegar H; Seja E; Villanueva A; Gomez-Navarro J; Glaspy JA; Cochran AJ; Ribas A
Clin Cancer Res; 2011 Jun; 17(12):4101-9. PubMed ID: 21558401
[TBL] [Abstract][Full Text] [Related]
4. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
[TBL] [Abstract][Full Text] [Related]
5. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
[TBL] [Abstract][Full Text] [Related]
6. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
Comin-Anduix B; Lee Y; Jalil J; Algazi A; de la Rocha P; Camacho LH; Bozon VA; Bulanhagui CA; Seja E; Villanueva A; Straatsma BR; Gualberto A; Economou JS; Glaspy JA; Gomez-Navarro J; Ribas A
J Transl Med; 2008 May; 6():22. PubMed ID: 18452610
[TBL] [Abstract][Full Text] [Related]
7. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma.
Ryu HS; Park YS; Park HJ; Chung YR; Yom CK; Ahn SH; Park YJ; Park SH; Park SY
Thyroid; 2014 Aug; 24(8):1232-40. PubMed ID: 24742251
[TBL] [Abstract][Full Text] [Related]
8. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study.
Niinisalo P; Oksala N; Levula M; Pelto-Huikko M; Järvinen O; Salenius JP; Kytömäki L; Soini JT; Kähönen M; Laaksonen R; Hurme M; Lehtimäki T
Ann Med; 2010; 42(1):55-63. PubMed ID: 19941414
[TBL] [Abstract][Full Text] [Related]
9. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment.
Furuzawa-Carballeda J; Lima G; Uribe-Uribe N; Avila-Casado C; Mancilla E; Morales-Buenrostro LE; Pérez-Garrido J; Pérez M; Cárdenas G; Llorente L; Alberú J
Transplant Proc; 2010 Nov; 42(9):3489-96. PubMed ID: 21094802
[TBL] [Abstract][Full Text] [Related]
10. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
[TBL] [Abstract][Full Text] [Related]
11. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
Kobayashi N; Kubota K; Kato S; Watanabe S; Shimamura T; Kirikoshi H; Saito S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A
Pancreatology; 2010; 10(5):631-40. PubMed ID: 21051918
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood.
Ikemoto T; Shimada M; Komatsu M; Yamada S; Saito Y; Mori H; Morine Y; Imura S; Bando Y; Utsunomiya T
Pancreas; 2013 Jan; 42(1):130-4. PubMed ID: 22722263
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma.
de Jong RA; Kema IP; Boerma A; Boezen HM; van der Want JJ; Gooden MJ; Hollema H; Nijman HW
Gynecol Oncol; 2012 Sep; 126(3):474-80. PubMed ID: 22668882
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of the anti-CTLA-4 antibody tremelimumab.
Ribas A
Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase and foxp3 expression in skin rejection of human hand allografts.
Hautz T; Brandacher G; Zelger B; Müller HG; Lee AW; Fuchs D; Margreiter R; Schneeberger S
Transplant Proc; 2009 Mar; 41(2):509-12. PubMed ID: 19328914
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
[TBL] [Abstract][Full Text] [Related]
17. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
Chevolet I; Speeckaert R; Haspeslagh M; Neyns B; Krüse V; Schreuer M; Van Gele M; Van Geel N; Brochez L
Br J Dermatol; 2014 Nov; 171(5):987-95. PubMed ID: 24814041
[TBL] [Abstract][Full Text] [Related]
18. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
19. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
20. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
